Bull case
Autolus Therapeutics is viewed favorably because its lead CAR-T therapy, obe-cel, is showing a compelling balance of efficacy and safety, with Phase 1 CARLYSLE data showing a 50% complete renal response in 3/6 patients at a median 11.4 months follow-up and 0% Grade 3+ CRS or ICANS, while the pivotal single-arm Phase 2 LUMINA trial enrolls 30 refractory lupus nephritis patients who have already failed more than 2 immunosuppressive therapies. The outlook is further strengthened by commercialization momentum, as Aucatzyl generated $26.2M in 1Q26 revenue, management reiterated 2026 revenue guidance of $120-135M, and the number of authorized treatment centers rose from 67 to 73 with growth to more than 80 still expected by YE2026. Additional upside comes from multiple de-risking and expansion catalysts, including long-term CARLYSLE follow-up expected at ACR Convergence in late 2026, LUMINA data guided to 2028, frontline consolidation evidence that could support NCCN guideline changes in 2027, and pediatric first-relapse expansion through the planned CATULUS study enlargement.